Location, location, location: Sub-cellular specific targeting of JNK as a novel therapy in breast cancer. [ 2018 - 2020 ]

Research Grant

Researchers: Dr David Croucher (Principal investigator)

Brief description The ‘triple negative’ breast cancer subtype is the most aggressive form of breast cancer, and unlike other subtypes, there are no drugs to specifically this subtype. While many potential drug targets have been identified, they cannot be utilised clinically because of other beneficial roles within the body. We are now deploying our innovative experimental platforms to specifically target the tumour promoting functions of a protein known as ‘JNK’, whilst retaining its beneficial functions.

Funding Amount $AUD 633,755.07

Funding Scheme Project Grants

Notes Standard Project Grant